← All countries · Europe
94%
MCV1
2025 · WHO/UNICEF estimate
90%
DTP3
2025 · WHO/UNICEF estimate
90%
IPV complete
2025 · WHO/UNICEF estimate
0%
HepB3
2018 · Administrative (country-reported)
0
Measles cases
2025 reported
14
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 0%2018 · Administrative (country-reported) | 0% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 98%2025 · WHO/UNICEF estimate | 98.3% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 90%2025 · WHO/UNICEF estimate | 90.2% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 98.3% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 90%2025 · WHO/UNICEF estimate | 90.2% | C · weak | |
| MCV1First dose of measles-containing vaccine | 94%2025 · WHO/UNICEF estimate | 94.7% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 93%2025 · WHO/UNICEF estimate | 89.5% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 94%2025 · WHO/UNICEF estimate | 94.7% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 0%2018 · Administrative (country-reported) | 0% | too few points | D · poor |
| HepB birthHepatitis B birth dose within 24 hours | 0%2018 · Administrative (country-reported) | 0% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 90%2025 · WHO/UNICEF estimate | 90.2% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 99.2%2025 · Administrative (country-reported) | 99.2% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 92%2025 · WHO/UNICEF estimate | 92.2% | A · strong | |
| RotaCRotavirus vaccine, complete series | 64%2025 · WHO/UNICEF estimate | 64.4% | too few points | C · weak |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2018 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | 0%2018 · Administrative (country-reported) | 0% | too few points | D · poor |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2018 · Administrative (country-reported) | 0% | too few points | D · poor |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 0%2018 · Administrative (country-reported) | 0% | too few points | D · poor |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 94%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 92%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 93%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 142025 | 35.2per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (37 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Adults with chronic conditions, older adults with chronic conditions | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 1 | M3 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 2 | M5 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 3 | M12 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers | Risk groups: Persons in households with a hepatitis B infected person, health care workers whose duties expose them to blood or blood products, patients who require frequent transfusions of blood products or undergo haemodialysis, IV drug users, MSM | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Risk groups: Persons in households with a hepatitis B infected person, health care workers whose duties expose them to blood or blood products, patients who require frequent transfusions of blood products or undergo haemodialysis, IV drug users, MSM | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12 | HPV administered to females and males | Gender neutral and switch to HPV9 from birth cohort 2011 |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | Gender neutral and switch to HPV9 from birth cohort 2011 |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y60 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-M59 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M18 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y12 | General/routine | |
| MPOXMpox (monkeypox) vaccine | 1 | Health workers | Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose regime used (minimum 28 days, longer is fine but not specifically encouraged), dose-sparing may be used if demand high. | |
| MPOXMpox (monkeypox) vaccine | 1 | Risk group(s) | Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose regime used (minimum 28 days, longer is fine but not specifically encouraged), dose-sparing may be used if demand high. | |
| MPOXMpox (monkeypox) vaccine | 2 | Health workers | Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose regime used (minimum 28 days, longer is fine but not specifically encouraged), dose-sparing may be used if demand high. | |
| MPOXMpox (monkeypox) vaccine | 2 | Risk group(s) | Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose regime used (minimum 28 days, longer is fine but not specifically encouraged), dose-sparing may be used if demand high. | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M3 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M5 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M12 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | W6 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M3 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M5 | General/routine | |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | M0-M6 | Catch-up children | Babies born Oct-Mar at birth, catch-up in Oct-Nov for babies born May-Sept |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | M0-M6 | General/routine | Babies born Oct-Mar at birth, catch-up in Oct-Nov for babies born May-Sept |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | M6-M23 | Risk group(s) | Age 6-23 mo Oct 1 with sever underlying conditions |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women in 3rd trimester from May 2019 | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 4 | Y4 | General/routine | |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 1 | Pregnant women | May be used for pregnant women in 3rd trimester if IPV indicated or Tdap shortage as of May 2019 | |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 5 | Y14 | General/routine | |
| VARICELLAVaricella vaccine | 1 | M18 | General/routine | Birth cohort 2019 and later |
| VARICELLAVaricella vaccine | 2 | M30 | General/routine | Birth cohort 2019 and later |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.